Interrogating signalling pathways to develop targeted therapies for adult cancer.
We are working to better understand aberrant signalling pathways in adult cancers. We use state-of-the-art techniques to identify unique components of cancer cells that can be exploited to develop 'molecularly targeted therapies'.
We aim to develop novel therapies that:
- are specific for cancer cells
- have little or no side-effects
- are well tolerated by adult cancer patients
We aim to deliver these into clinics for the benefit of patients.
Our research areas
We have team leaders working in the following research areas:
- Genomics and Epigenetics
- DNA and cell damage repair and response
- Target discovery and validation
- Prognostic and predictive biomarkers
- Ligand and growth factor dependant signalling
- Stem cells and cancer
We have particular strength in the following cancers: bladder, breast, adult leukaemia, hepatobiliary cancer, ovarian, prostate and sarcoma.
Clinical trials in adults
We have run clinical trials for Bladder cancer, Hepatocellular cancer, and Sarcoma.